...
首页> 外文期刊>Cureus. >Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment
【24h】

Miller Fisher Syndrome in the COVID-19 Era – A Novel Target Antigen Calls for Novel Treatment

机译:Covid-19时代的Miller Fisher综合症 - 一种新的靶向抗原调用新型治疗

获取原文
           

摘要

Although Miller Fisher syndrome cases have been published in this coronavirus disease 2019 (COVID-19) pandemic, anti-GQ1b antibody has not been identified so far. A direct proof of association is not yet available since the exact pathophysiology is not known. Using a proof of contradiction argument, lack of GQ1b serves as the indirect proof that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is probably the infection preceding demyelination. A novel antigen has yet to be described.
机译:虽然米勒Fisher综合征案件已在该冠状病毒疾病2019(Covid-19)大流行中,但到目前为止还没有鉴定抗GQ1B抗体。 由于确切的病理生理学尚未知道,尚未使用直接关联证明。 利用矛盾论证证明,缺乏GQ1B用作间接证明,严重急性呼吸综合征冠状病毒2(SARS-COV-2)可能是前一种脱髓鞘的感染。 尚未描述一种新的抗原。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号